^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
191MO - KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs
Published date:
05/07/2023
Excerpt:
In the phase III KEYNOTE-355 study (NCT02819518), first-line treatment with pembro + chemo resulted in statistically significant and clinically meaningful improvements in PFS and OS versus placebo + chemo in patients (pts) with advanced TNBC with PD-L1 combined positive score (CPS) ≥10....Pts with...metastatic TNBC were randomized 2:1 to pembro (200 mg Q3W) or placebo for 35 cycles in combination with chemo (nab-paclitaxel, paclitaxel, or gemcitabine/carboplatin)....In this analysis, PFS per RECIST v1.1 by BICR and OS were evaluated in (a) pts who received pembro + chemo, achieved a best objective response of CR, PR, or SD lasting ≥24 wk...there was evidence of antitumor activity in pts who had immune-mediated AEs, overall and by tumor PD-L1 CPS (Table).
Secondary therapy:
albumin-bound paclitaxel; gemcitabine; carboplatin; paclitaxel
Trial ID:
Source:
Title:
Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases
Published date:
11/17/2020
Excerpt:
...pembrolizumab (pembro) monotherapy vs single-agent chemotherapy (chemo) in patients with previously treated metastatic triple-negative breast cancer (mTNBC)...with the greatest benefit observed in patients with PD-L1 CPS ≥20 tumors...pembro monotherapy showed a benefit vs single-agent chemo in patients with increasing PD-L1 tumor enrichment...
Trial ID:
Source:
Title:
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit
Published date:
07/07/2022
Excerpt:
We identified 29 patients with mTNBC treated with pembrolizumab or atezolizumab, either alone (n = 9) or in combination with chemotherapy (n = 14) or targeted therapy (n = 6), who had tumor tissue and/or blood available before ICI therapy for whole-exome sequencing....Progression-free survival and OS were longer in patients with high programmed death-ligand 1 expression and tumor mutational burden....This study identified potential biomarkers of response to ICIs among patients with mTNBC...
Secondary therapy:
Chemotherapy
DOI:
10.1200/PO.21.00413
Source:
Title:
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit
Published date:
07/07/2022
Excerpt:
We identified 29 patients with mTNBC treated with pembrolizumab or atezolizumab, either alone (n = 9) or in combination with chemotherapy (n = 14) or targeted therapy (n = 6), who had tumor tissue and/or blood available before ICI therapy for whole-exome sequencing....Progression-free survival and OS were longer in patients with high programmed death-ligand 1 expression and tumor mutational burden....This study identified potential biomarkers of response to ICIs among patients with mTNBC...
DOI:
10.1200/PO.21.00413
Source:
Title:
Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086
Published date:
11/17/2020
Excerpt:
In this exploratory biomarker analysis from KEYNOTE-086, higher levels of PD-L1, GEP, TMB, CD8 IHC, sTILs, and the glycolysis signature were associated with increased response to pembrolizumab monotherapy.
Trial ID:
Source:
Title:
Abstract P3-10-09: Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro)+chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial
Excerpt:
Endpoints were pCR rate by ypT0 ypN0 and ypT0/Tis ypN0 and objective response rate (ORR; RECIST v1.1) after the first 4 cycles of NAT (taxane±carboplatin+pembro) by MRI....Higher quantities of pretreatment sTILs and PD-L1 CPS and on-treatment sTILs were significantly associated with higher pCR rates and ORR in primary TNBC treated with pembro and NAT.
Secondary therapy:
carboplatin
DOI:
10.1158/1538-7445.SABCS18-P3-10-09
Trial ID:
